Outlook Therapeutics Secures FDA Nod for LYTENAVA, First Approved Ophthalmic Bevacizumab — Outlook Therapeutics, Inc.

Event summary

Outlook Therapeutics' LYTENAVA™ received FDA approval on July 24, 2026 for treating wet AMD.
LYTENAVA is the first and only FDA-approved ophthalmic formulation of bevacizumab specifically developed for retinal diseases.
The approval grants Outlook 12 years of market exclusivity under the Biologics Price Competition and Innovation Act (BPCIA).
Outlook aims to launch LYTENAVA in the U.S. before year-end, targeting the $8.5 billion anti-VEGF retina market.

The big picture

Outlook Therapeutics’ FDA approval for LYTENAVA marks a strategic shift in the wet AMD treatment landscape, moving away from repackaged intravenous formulations to an ophthalmic-specific product. The approval positions Outlook to capture significant market share in the $8.5 billion U.S. retina market, leveraging 12 years of exclusivity under BPCIA. This development underscores the growing demand for FDA-approved therapies in retinal care, where consistency and regulatory oversight are critical.

What we're watching

Market Penetration: Whether Outlook can establish LYTENAVA as the standard FDA-approved bevacizumab therapy in a market dominated by repackaged formulations.
Reimbursement Dynamics: The pace at which reimbursement and patient support programs expand access to LYTENAVA across the U.S.
Competitive Response: How existing players in the $8.5 billion anti-VEGF retina market react to Outlook’s FDA-approved offering.